A report from a patient advocacy group found the future of medical cannabis in the states is hazy unless costs are decreased, product safety standards are improved, and civil rights are strengthened for patients and prescribers.
Menu
A report from a patient advocacy group found the future of medical cannabis in the states is hazy unless costs are decreased, product safety standards are improved, and civil rights are strengthened for patients and prescribers.
The Georgia Commission for Access to Medical Cannabis recently granted two corporations (Trulieve and Botanical Sciences) the licenses to grow cannabis products in the state.